[{"text":null,"message_id":"?","context_id":"10e4079d-28cd-3e4b-a304-21819da84515","post_id":"v-69f70237-124f-3ea9-acd0-fc922af945e2_c-78318bf7-a97d-3be7-aa64-e0595ce84383_a-10e4079d-28cd-3e4b-a304-21819da84515","upvotes":"0","downvotes":"0","reports":"0","replies":"0","author_name":"Newsroom Bot","author_img":"https:\/\/s.yimg.com\/ge\/myc\/newsroom_app_icon_ios.png","author_guid":"1","score":0,"context_meta":{"post_id":"v-69f70237-124f-3ea9-acd0-fc922af945e2_c-78318bf7-a97d-3be7-aa64-e0595ce84383_a-10e4079d-28cd-3e4b-a304-21819da84515","post_url":"https:\/\/www.yahoo.com\/newsroom\/vibes\/world-news\/pfizer-executives-changing-tune-approach-6a354ui","author":"captainunderoos","provider":"Business Insider","provider_url":null,"provider_image":"","lead_attribution":"provider","link":"http:\/\/uk.businessinsider.com\/pfizers-cancer-drug-combination-trials-with-immunotherapy-and-targeted-drugs-2018-5","imgresolutions":[{"url":"https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/SqJtjzjMc8zi4xelcsAwcg--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD0zNjA7dz02NDA7\/https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/cauE1UCtvXvOwdve4H_YNQ--\/dz0xMTkwO2g9NTk1O3RhZz1vcmlnaW5hbDthcHBpZD15bmV3cw--\/http:\/\/streambe.zenfs.com\/streambe\/streambe_10e4079d-28cd-3e4b-a304-21819da84515-590290829.jpeg","height":360,"width":640,"tag":"fit-width-640"},{"url":"https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/Rx.oiy8dRFjGN94PRBkTFg--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD01OTU7dz0xMTkwOw--\/https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/cauE1UCtvXvOwdve4H_YNQ--\/dz0xMTkwO2g9NTk1O3RhZz1vcmlnaW5hbDthcHBpZD15bmV3cw--\/http:\/\/streambe.zenfs.com\/streambe\/streambe_10e4079d-28cd-3e4b-a304-21819da84515-590290829.jpeg","height":595,"width":1190,"tag":"original"}],"img":"https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/cauE1UCtvXvOwdve4H_YNQ--\/dz0xMTkwO2g9NTk1O3RhZz1vcmlnaW5hbDthcHBpZD15bmV3cw--\/http:\/\/streambe.zenfs.com\/streambe\/streambe_10e4079d-28cd-3e4b-a304-21819da84515-590290829.jpeg","imgw":1190,"imgh":595,"title":"Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be where the field is headed","summary":"We're learning more about how a new class of cancer drugs that targets the body's immune system work in some patients, but not in others.\u00a0 Initially, the healthcare industry was really excited about seeing how pairing up two drugs that target the immune system work together to treat certain forms of cancer. But now that more data has come out, researchers at Pfizer are shifting their attention toward combining these immune system-acting drugs with targeted therapies that act on genetic mutations in cancer patients to see if more people respond.\u00a0 When a new form of cancer treatment known as cancer immunotherapy first hit the spotlight, it came with a big promise.\u00a0 In the case of Jimmy Carter,","published_at":1527174431,"content_id":"10e4079d-28cd-3e4b-a304-21819da84515","content_url":"http:\/\/uk.businessinsider.com\/pfizers-cancer-drug-combination-trials-with-immunotherapy-and-targeted-drugs-2018-5","content_published_at":1527138000,"content_time":1527138000,"content_relative_time":17,"reaction_count":0,"vibe_name":"World News","vibe_id":"69f70237-124f-3ea9-acd0-fc922af945e2","content_type":"link","aspect":null},"created_at":0,"comment_time":17,"comment_relative_time":17,"bot":true,"whitelisted_commenter":false}]